Reps. Dingell, Stupak expand FDA inspection inquiry
Executive Summary
With the expansion of the Energy and Commerce Committee's two-year inquiry into FDA's alleged manufacturer inspection failures, pharma can assume that any GMP violations will lead to questions of their core bioequivalence verification methods. Rep. John Dingell and fellow Michigan Democrat Rep. Bart Stupak sent a letter to Commissioner Andrew von Eschenbach Oct. 8 regarding Actavis Totowa's Aug. 1 recall of all drugs manufactured at the Little Falls, N.J. plant (1"The Pink Sheet," Aug. 11, 2008, p. 24). The letter requests a number of FDA documents, including a list of laboratories performing BE studies for Actavis products and FDA personnel responsible for inspecting those labs. The inquiry comes on the heels of an ongoing investigation into allegations of fraud related to Ranbaxy bioequivalence and stability data in its ANDAs (2"The Pink Sheet," July 28, 2008, p. 27)
You may also be interested in...
GMP Storm Cloud: Generic Firms May Get Further Scrutiny After Actavis Recall
The latest in a series of recalls for Actavis' Little Falls, N.J. facility comes at an awkward time for the generics industry and FDA, and could fuel a congressional push towards tighter oversight of pharmaceutical production
FDA Should Recall Drugs Subject To GMP Violations, Rep. Dingell Suggests
The House Energy & Commerce Committee is suggesting that it is not enough for FDA to send a warning letter to a company in violation of good manufacturing practices
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.